Study Shows MuGard(R) is More Effective Than Sham-Control at Reducing Mouth and Throat Soreness Associated With Oral Mucositis in Head and Neck Cancer Patients

[GlobeNewswire] – WALTHAM, Mass. — AMAG Pharmaceuticals, Inc. today announced the publication of data from a multi-institutional trial of MuGard in the online edition of the journal Cancer available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.285 more

View todays social media effects on AMAG

View the latest stocks trending across Twitter. Click to view dashboard

See who AMAG is hiring next, click here to view